NYSE:EWMedical Equipment
Edwards Lifesciences Nears SAPIEN M3 Decision As Big Money Moves
Edwards Lifesciences (NYSE:EW) is awaiting an FDA decision on its SAPIEN M3 Transcatheter Mitral Valve Replacement system, a potential milestone for its structural heart portfolio.
Institutional investors have been building positions around this catalyst, with recent order flow suggesting heightened attention on the upcoming regulatory outcome.
The company has also been active with a share repurchase program, signaling confidence from management in the long term outlook.
Edwards...